Mecasermin vs IGF-1 LR3

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicMecaserminIGF-1 LR3
What it is

Not a peptide: a protein, larger than a peptide, often looked up alongside peptides2,5

Human IGF-1 made by recombinant DNA technology in bacteria: a single chain of 70 amino acids with three disulfide bridges, according to the label.2

Not a peptide: a protein, larger than a peptide, often looked up alongside peptides3,5

Human IGF-1 with arginine in place of glutamic acid at position 3 and a 13-amino-acid extension at the start, 83 amino acids in all, according to FDA’s substance registry.3

FDA status

FDA-approved

FDA-approved as Increlex for severe primary IGF-1 deficiency in children1,2

FDA-approved. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005. The label has no boxed warning.1,2

Is mecasermin FDA-approved?

Not FDA-approved

No FDA approval reported; studied only in cells and animals3,4

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.3,4

Is IGF-1 LR3 FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.6

Not among the six peptides the policy lists.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 LR3 is not among them.6,7

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list IGF-1 LR3.4

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study Five clinical studies, four open-label and one double-blind and placebo-controlled, in 71 children with severe primary IGF-1 deficiency, pooled in the label, in which growth rate rose from a mean of 2.8 to 8.0 cm a year in the first year of treatment.2

Animal and lab studies only

  • Animal or laboratory research Cell studies from 1992 in which IGF-1 analogues with an added extension, including the arginine-3 form, were more potent than natural IGF-1 at stimulating protein and DNA synthesis in rat muscle cells.8
  • Animal or laboratory research A 2025 study in growth-restricted fetal sheep, in which a week of IGF-1 LR3 did not improve growth.9
Records collected

9 ClinicalTrials.gov records and 18 PubMed records collected

0 ClinicalTrials.gov records and 1 PubMed record collected

Area of study

Hormones, Bone and growth2

Hormones3

Latest dated events
  1. DailyMed publishes version 4 of the Increlex label, the version cited here.2
  2. FDA approves Increlex, application 021839, according to Drugs@FDA.1
  1. A study reports that IGF-1 LR3 did not improve growth in growth-restricted fetal sheep.9
  2. Doping-control researchers report identifying a tagged form of IGF-1 LR3 and state that its effects in humans have not been described.10
  3. Researchers describe IGF-1 analogues with an added extension, including the arginine-3 form, made as research tools.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  3. 3
    Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 ↗

    Federal Register · Official source · Source checked November 16, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency (1992) · PMID 1378742 ↗

    Journal of Molecular Endocrinology · Official source · Source checked November 16, 2026

  9. 9
    IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (2025) · PMID 39679943 ↗

    American Journal of Physiology. Endocrinology and Metabolism · Official source · Source checked November 16, 2026

  10. 10
    Detection of His-tagged Long-R3-IGF-I in a black market product (2010) · PMID 20675162 ↗

    Growth Hormone & IGF Research · Official source · Source checked November 16, 2026